Received May 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
Rash; Headache; Chills; Nausea; Dizziness; Irregular heart beat; This non-serious case was reported by a consumer via call center representative and described the occurrence of rash in a elderly female patient who received Herpes zoster (Shingrix) for prophylaxis. On 05-MAY-2025, the patient received the 1st dose of Shingrix. In MAY-2025, an unknown time after receiving Shingrix, the patient experienced rash (Verbatim: Rash), headache (Verbatim: Headache), chills (Verbatim: Chills), nausea (Verbatim: Nausea), dizziness (Verbatim: Dizziness) and heart rate irregular (Verbatim: Irregular heart beat). The outcome of the rash, headache, chills, nausea, dizziness and heart rate irregular were unknown. It was unknown if the reporter considered the rash, headache, chills, nausea, dizziness and heart rate irregular to be related to Shingrix. It was unknown if the company considered the rash, headache, chills, nausea, dizziness and heart rate irregular to be related to Shingrix. Additional Information: GSK Receipt Date: 06-MAY-2025 The patient self-reported this case The patient received her first dose of Shingrix yesterday morning and after the dose, she experienced irregular heartbeat, rash, headache, chills, nausea, and dizziness.
Test Date: 202505; Test Name: heart rate irregular; Result Unstructured Data: (Test Result:irregular,Unit:unknown,Normal Low:,Normal High:)